Lewis Stuart Intends to Resign as Chief Commercial Officer of NovaBay Pharmaceuticals, Inc., Effective July 23, 2018
April 26, 2018 at 09:31 pm
Share
On April 23, 2018, Lewis Stuart announced the board of directors of NovaBay Pharmaceuticals, Inc. of his intent to resign as Chief Commercial Officer effective July 23, 2018. Mr. Stuart has agreed to assist in the transition of the new sales executive and to continue supporting the managed care and clinical study initiatives until his resignation is effective.
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.
NOVABAY PHARMACEUTICALS, INC. 
